The Roche-Syapse collaboration to develop analytics programs may enable health systems to measure the impact of precision therapies, said Damon Hostin, CEO of the Precision Medicine Alliance.
Hostin oversees the bioinformatics partnership between two of the nation’s largest nonprofits—Dignity Health and Catholic Health Initiatives—and is in charge of integration of oncology data between the health systems. The network describes itself as the largest community-based precision medicine program in the U.S.